GT
AGRX

Glenmede Trust’s Agile Therapeutics AGRX Stock Holding History

Glenmede Trust’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5
Closed -$41K – 2836
2017
Q3 		$41K Hold
5
– – ﹤0.01% 1721
2017
Q2 		$29K Hold
5
– – ﹤0.01% 1803
2017
Q1 		$29K Hold
5
– – ﹤0.01% 1803
2016
Q4 		$53K Hold
5
– – ﹤0.01% 1590
2016
Q3 		$65K Hold
5
– – ﹤0.01% 1526
2016
Q2 		$70K Buy
+5
New +$68.5K ﹤0.01% 1460

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Glenmede Trust's AGRX Position: Q4 2017 in Review

Glenmede Trust sold out of Agile Therapeutics (AGRX) in Q4 2017, closing a stake of 5 shares — an estimated $41K sold.

Glenmede Trust first reported a position in AGRX in Q2 2016 and held it in 6 quarters. The position peaked at $70K in Q2 2016. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2017.

  • Glenmede Trust reported no remaining Agile Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Glenmede Trust sold 5 Agile Therapeutics shares in Q4 2017, an estimated $41K.
  • Glenmede Trust first reported a position in Agile Therapeutics in Q2 2016 and held it in 6 quarters.
  • Glenmede Trust's Agile Therapeutics position peaked at $70K in Q2 2016.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2017.

Based on Glenmede Trust's 13F filing for Q4 2017, filed 15 Feb 2018.